Search
RPI-MN
go.drugbank.com/drugs/DB17957ExperimentalRPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties. … [A260132] Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.[L47107]
Synonyms: RPI-MNMatrix-M
go.drugbank.com/drugs/DB16369InvestigationalMatrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax. … [L27981] This compound is administered alongside vaccines to enhance biological functions: creating robust and long-lasting immune responses that may allow for dose-sparing of vaccines.
Tovecimig
go.drugbank.com/drugs/DB30220InvestigationalNOV1501 is under investigation in clinical trial NCT03292783 (This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended … NOV1501 is a biologic drug.
LNP-nCoVsaRNA Vaccine
go.drugbank.com/drugs/DB15799ExperimentalThe vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly funded by UK Research and Innovation. … LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells.
Nomifensine
go.drugbank.com/drugs/DB04821ApprovedWithdrawnThe approved application holder removed Merital capsules from the market on January 23, 1986. … Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia.
Galicaftor
go.drugbank.com/drugs/DB14894Investigationalin Patients With Cystic Fibrosis.). … Galicaftor is under investigation in clinical trial NCT03540524 (A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737
KER-047
go.drugbank.com/drugs/DB19111InvestigationalKER-047 is under investigation in clinical trial NCT05927012 (A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (
Latrunculin A
go.drugbank.com/drugs/DB02621InvestigationalLatrunculin A is an actin binding macrolide purified from the red sea sponge Latrunculia magnifica. It is under investigation for the treatment of cancer. … It disrupts actin polymerization, prevents mitotic spindle formation and thus cell replication.
ENTR-601-44
go.drugbank.com/drugs/DB17836InvestigationalENTR-601-44 is an exon 44 skipping phosphorodiamidate morpholino oligonucleotide (PMO). Developed by Entrada Therapeutics, it was investigated for the treatment of Duchenne muscular dystrophy.[L46641]
GB-13
go.drugbank.com/drugs/DB18387ExperimentalGB-13 is a genetically engineered recombinant protein consisting of an IL13Ra2-targeted genetically engineered mutant of IL-13 and PE4E, a derivative of Pseudomonas exotoxin A.